

Masaki Yoshida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6729591/publications.pdf>

Version: 2024-02-01

12
papers

544
citations

1039880

9
h-index

1199470

12
g-index

12
all docs

12
docs citations

12
times ranked

579
citing authors

#	ARTICLE	IF	CITATIONS
1	Sildenafil, a new 5 α -adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. <i>BJU International</i> , 2006, 98, 1019-1024.	1.3	245
2	Vibegron, a Novel Potent and Selective β ₃ -Adrenoceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study. <i>European Urology</i> , 2018, 73, 783-790.	0.9	100
3	Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo- and tamsulosin-controlled 12-week study in Asian men. <i>International Journal of Urology</i> , 2013, 20, 193-201.	0.5	76
4	Frontal white matter hyperintensity predicts lower urinary tract dysfunction in older adults with amnesic mild cognitive impairment and Alzheimer's disease. <i>Geriatrics and Gerontology International</i> , 2016, 16, 167-174.	0.7	30
5	Clinical characteristics and useful signs to differentiate detrusor underactivity from bladder outlet obstruction in men with non-neurogenic lower urinary tract symptoms. <i>International Journal of Urology</i> , 2020, 27, 47-52.	0.5	23
6	Efficacy of novel β ₃ -adrenoceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study. <i>International Journal of Urology</i> , 2019, 26, 369-375.	0.5	17
7	Clinical diagnostic criteria for detrusor underactivity: A report from the Japanese Continence Society working group on underactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 13-16.	0.6	14
8	Variability of post-void residual urine volume and bladder voiding efficiency in patients with underactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 51-55.	0.6	13
9	Frontal Lobe Function Correlates with One-Year Incidence of Urinary Incontinence in Elderly with Alzheimer Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 567-574.	1.2	10
10	Comparison of Sildenafil versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2017, 9, 176-186.	0.6	7
11	Cardiovascular safety of vibegron, a new β ₃ -adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study. <i>Neurology and Urodynamics</i> , 2021, 40, 1651-1660.	0.8	5
12	Tadalafil Improves Nocturia and Nocturia-Related Quality of Life in Patients with Benign Prostatic Hyperplasia (KYU-PRO Study). <i>Urologia Internationalis</i> , 2020, 104, 587-593.	0.6	4